Erasca, a San Diego, CA-based cancer therapeutics company, completed a $36m extension of its Series B financing round, which brings the total round to $236m.
This financing brings the total capital raised by the company to $300m. New investors include Partner Fund Management and OrbiMed.
Erasca will use the proceeds to finance the clinical development of multiple promising oncology programs, continue driving corporate development efforts and further advance its in-house drug discovery pipeline.
Founded in 2018 by Jonathan E. Lim, M.D., chairman, CEO, the company has assembled a pipeline of precision therapies directed at undisclosed targets through in-house drug discovery as well as active pipeline expansion via collaborations with academic and biopharmaceutical organizations.
Investors also include ARCH Venture Partners, City Hill Ventures and Cormorant Asset Management.